Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):541–545. doi: 10.1038/bjc.1994.98

rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.

R Rampling 1, W Steward 1, J Paul 1, M A Macham 1, E Harvey 1, D Eckley 1
PMCID: PMC1968853  PMID: 8123485

Abstract

Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover study of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was performed in patients receiving BCNU for relapsed glioblastoma, to investigate whether the resulting haematological toxicity profile could be modified by rhGM-CSF. Adequate data for analysis were obtained in 13 patients. Following BCNU, the nadir neutrophil count was higher in 12 out of 13 patients during the rhGM-CSF-protected cycles compared with the unprotected cycles. The median nadir was also significantly higher (1.79, CI 0.76-3.52, P < 0.005). Five episodes of neutropenia (< 2 x 10(9) l-1) occurred during the unprotected cycles compared with none in the rhGM-CSF-protected cycles (P = 0.076). There was no evidence of any effect on platelets. This result shows that the haematological toxicity profile following therapeutic doses of BCNU can be modified. It suggests that rhGM-CSF and other growth factors should be investigated for clinical efficacy in chemotherapy using nitrosoureas.

Full text

PDF
541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. S., Griffin J. D., Elias A., Socinski M. A., Ryan L., Cannistra S. A., Oette D., Whitley M., Frei E., 3rd, Schnipper L. E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 8;319(10):593–598. doi: 10.1056/NEJM198809083191001. [DOI] [PubMed] [Google Scholar]
  2. Brandt S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E. J., Bast R. C., Jr, Gilbert C. J., Oette D. H. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 7;318(14):869–876. doi: 10.1056/NEJM198804073181401. [DOI] [PubMed] [Google Scholar]
  3. Dunlop D. J., Steward W. P. Recombinant human granulocyte macrophage colony-stimulating factor: current status of clinical trials and potential future applications. Anticancer Drugs. 1991 Aug;2(4):327–337. doi: 10.1097/00001813-199108000-00001. [DOI] [PubMed] [Google Scholar]
  4. Edmonson J. H., Long H. J., Jeffries J. A., Buckner J. C., Colon-Otero G., Fitch T. R. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J Natl Cancer Inst. 1989 Oct 4;81(19):1510–1512. doi: 10.1093/jnci/81.19.1510-a. [DOI] [PubMed] [Google Scholar]
  5. Gregor A., Rampling R., Aapro M., Malmström P., Whittle I. R., Rye R., Stewart M., Sellar R., Demierre B., Ironside J. W. Phase II study of tauromustine in malignant glioma. Eur J Cancer. 1992;28A(12):1959–1962. doi: 10.1016/0959-8049(92)90236-u. [DOI] [PubMed] [Google Scholar]
  6. Hochberg F. H., Parker L. M., Takvorian T., Canellos G. P., Zervas N. T. High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981 Apr;54(4):455–460. doi: 10.3171/jns.1981.54.4.0455. [DOI] [PubMed] [Google Scholar]
  7. Hoshino T., Ito S., Asai A., Shibuya M., Prados M. D., Dodson B. A., Davis R. L., Wilson C. B. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine. Int J Cancer. 1992 Jan 2;50(1):1–5. doi: 10.1002/ijc.2910500102. [DOI] [PubMed] [Google Scholar]
  8. Kornblith P. L., Walker M. Chemotherapy for malignant gliomas. J Neurosurg. 1988 Jan;68(1):1–17. doi: 10.3171/jns.1988.68.1.0001. [DOI] [PubMed] [Google Scholar]
  9. Lieschke G. J., Burgess A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med. 1992 Jul 2;327(1):28–35. doi: 10.1056/NEJM199207023270106. [DOI] [PubMed] [Google Scholar]
  10. Lieschke G. J., Burgess A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med. 1992 Jul 9;327(2):99–106. doi: 10.1056/NEJM199207093270207. [DOI] [PubMed] [Google Scholar]
  11. Mbidde E. K., Selby P. J., Perren T. J., Dearnaley D. P., Whitton A., Ashley S., Workman P., Bloom H. J., McElwain T. J. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer. 1988 Dec;58(6):779–782. doi: 10.1038/bjc.1988.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Stenning S. P., Freedman L. S., Bleehen N. M. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer. 1987 Jul;56(1):89–90. doi: 10.1038/bjc.1987.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Steward W. P., Scarffe J. H., Austin R., Bonnem E., Thatcher N., Morgenstern G., Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer. 1989 Jan;59(1):142–145. doi: 10.1038/bjc.1989.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Steward W. P., Scarffe J. H., Dirix L. Y., Chang J., Radford J. A., Bonnem E., Crowther D. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. Br J Cancer. 1990 May;61(5):749–754. doi: 10.1038/bjc.1990.167. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES